Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multidimensional Longitudinal Assessment of Oral Mucositis Burden and Functional Impact in Head and Neck Cancer Patients Undergoing Radiotherapy or Chemoradiotherapy: A Retrospective and Exploratory Observational Study.

Cancers·2026

Same author

Exploratory Analysis of the Neutrophil-to-Lymphocyte Ratio (NLR) and Mucositis Severity in Head and Neck Cancer Patients Undergoing Radiotherapy-Based Treatment: A Retrospective Study.

Journal of clinical medicine·2026

Same author

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.

Melanoma research·2025

Same author

Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.

Journal of advanced research·2025

Same author

Novel De Novo <i>BRCA2</i> Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

International journal of molecular sciences·2025

Same author

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

British journal of haematology·2024

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Lenalidomide: a new therapy for multiple myeloma.

Antonio Palumbo¹, Jesús San Miguel, Pieter Sonneveld

¹Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy. appalumbo@yahoo.com

Cancer Treatment Reviews

|January 31, 2008

Summary

Lenalidomide, an immunomodulatory drug, shows high effectiveness in treating relapsed or refractory multiple myeloma. Ongoing trials aim to optimize its use and personalize treatment strategies for this complex blood cancer.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jul 7, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Multiple myeloma management has rapidly evolved.
Cytogenetic, molecular, and proteomic advancements enhance understanding of myeloma pathophysiology and prognosis.
Multiple myeloma is a heterogeneous malignancy.

Purpose of the Study:

To review the evolving landscape of multiple myeloma management.
To highlight the role of novel immunomodulatory drugs like lenalidomide.
To discuss ongoing research for optimal and personalized treatment strategies.

Main Methods:

Review of recent advancements in multiple myeloma research and treatment.
Analysis of clinical data on lenalidomide efficacy, particularly in combination therapy.
Discussion of ongoing clinical trials exploring lenalidomide's optimal use.

Main Results:

Lenalidomide, combined with dexamethasone, is highly effective in patients with conventional therapy-resistant multiple myeloma.
New immunomodulatory drugs interrupt myeloma growth and survival pathways.
Significant progress in understanding prognostic markers.

Conclusions:

Lenalidomide represents a significant advancement in multiple myeloma treatment.
Further research is crucial to define optimal lenalidomide use and personalized treatment approaches.
Future treatments may be tailored based on prognostic markers and patient comorbidities.